Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: A phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 6, 2008, Pages 1075-1083

  Font, Albert ^a   Salazar, Ramon ^b   Maurel, Joan ^c   Taron, Miquel ^a   Ramirez, Jose Luis ^a   Tabernero, Josep ^b   Gallego, Rosa ^c   Casado, Esther ^b   Manzano, Jose Luis ^a   Carcereny, Enric ^c   Guix, Marta ^b   Fernández Llamazares, Jaume ^a   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

CPT 11; Docetaxel; Dose limiting toxicity; Phase I; Polymorphisms

Indexed keywords

ATROPINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CHOLINERGIC SYMPTOM; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DNA POLYMORPHISM; DNA REPAIR; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSPNEA; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; GENE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UGT1A1 GENE; VOMITING; XPD GENE; XRCC3 GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 52049103354     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0700-3     Document Type: Article

References (31)

1. JA Ajani MB Fodor SA Tjulandin VM Moiseyenko Y Chao SC Filho A Maijlis S Assadourian E Van Cutsem 2005 Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma J Clin Oncol 23 5660 5667
2. Y Ando H Saka M Ando T Sawa K Muro H Ueoka A Yokoyama S Saitoh K Shimokata Y Yoshinori Hasegawa 2000 Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921 6926
3. N Boku A Ohtsu Y Shimada Narikazu Boku K Shirao S Seki H Saito Y Sakata I Hyodo 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 323
4. WL De Laat NG Jaspers JH Hoeijmakers 1999 Molecular mechanism of nucleotide excision repair Genes Dev 13 7 768 785
5. R De las Peñas M Sanchez-Ronco V Alberola M Taron C Camps R Garcia-Carbonero B Massuti C Queralt M Botia R Garcia-Gomez D Isla M Cobo M Santarpia F Cecere P Mendez JJ Sánchez R Rosell 2006 Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients Ann Oncol 17 668 675
6. A Font JM Sanchez R Rosell M Taron E Martinez M Guillot JL Manzano M Margeli A Barnadas A Abad 2002 Phase I study of weekly CPT-11(irinotecan)/ docetaxel in patients with advanced solid tumors. Lung Cancer 37 213 218
7. A Font JM Sanchez M Taron E Martinez-Balibrea JJ Sanchez JL Manzano M Margelí M Richardet A Barnadas A Abad R Rosell 2003 Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism Invest New Drugs 21 435 443
8. JF Gagne V Montminy P Belanger K Journault G Gaucher C Guillemette 2002 Common human UGT1A1 polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxicamptothecin (SN-38). Mol Pharmacol 62 608 617
9. JF Gagnon O Bernard L Villeneuve B Têtu C Guillemette 2006 Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer Clin Cancer Res 12 1850 1858
10. S Gurubhagavatula G Liu S Park W Zhou L Su JC Wain TJ Lynch DS Neuberg DC Christiani 2004 XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy J Clin Oncol 22 2594 2601
11. DH Ilson L Saltz P Enzinger Y Huang A Kornblith M Gollub E ÓReilly G Schwartz J DeGroff G Gonzalez DP Kelsen 1999 Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer J Clin Oncol 17 3270 3275
12. F Innocenti SD Undevia L Iyer PX Chen S Das M Kocherginsky T Karrison L Janisch J Ramirez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 1382 1388
13. D Isla C Sarries R Rosell G Alonso M Domine M Taron G Lopez-Vivanco C Camps M Botia L Nuñez M Sanchez-Ronco JJ Sanchez M Lopez-Brea I Barneto A Paredes B Medina A Artal P Lianes 2004 Single nucleotde polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann Oncol 15 1194 1203
14. L Iyer D Hall S Das 1999 Phenotype-genotype correlation of in-vitro SN-38 (active metabolite of irinotecan) and bilirubin glucoronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 576 582
15. E Marcuello A Altés A Menoyo E Del Rio M Gómez-Pardo M Baiget 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678 682
16. G Matullo D Palli M Peluso S Guarrera S Carturan E Celentano V Krogh A Munnia R Tumino S Polidoro A Piazza P Vineis 2001 XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects Carcinogenesis 22 1437 1445
17. DJ Park J Stoehlmacher W Zhang DD Tsao-Wei S Groshen HJ Lenz 2001 A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer Cancer Res 61 8654 8658
18. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
19. K Ridwelski T Gebauer J Fahlke H Kröning E Kettner F Meyer K Eichelmann H Lippert 2001 Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 12 47 51
20. P Ross M Nicolson D Cunningham J Valle M Seymour P Harper T Price H Anderson T Iveson T Hickisk F Lofts A Norman 2002 Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 1996 2004
21. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani R Morant MM Borner R Herrmann H Honegger F Cavalli P Alberto M Castiglione A Goldhirsch 2000 Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute Of Oncology (EIO) Ann Oncol 11 301 306
22. A Ruzzo F Graziano K Kawakami G Watanabe D Santini V Catalano R Bisonni E Canestrari R Ficarelli ET Menichetti D Mari E Testa R Silva B Vincenzi P Giordani S Cascinu L Giustini G Tonini M Magnani 2006 Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy J Clin Oncol 24 1883 1891
23. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. doi:10.1038/sj.tpj.6500463
24. K Shirao Y Shimada H Kondo D Saito T Yamao H Ono T Yokoyama H Fukuda M Oka Y Watanabe A Ohtsu N Boku T Fujii Y Oda K Muro S Yoshida 1997 Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer J Clin Oncol 15 921 927
25. MR Spitz X Wu Y Wang LE Wang S Shete CI Amos Z Guo L Lei H Mohrenweiser Q Wei 2001 Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients Cancer Res 61 1354 1357
26. G Toffoli E Cecchin G Corona A Russo A Buonadonna M D̈Andrea LM Pasetto S Pessa D Errante V De Pangher M Giusto M Medici F Gaion P Sandri E Galligioni S Bonura M Boccalon P Biason S Frustaci 2006 The role of UGT1A*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer J Clin Oncol 24 3061 3068
27. Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group J Clin Oncol 24 4991 4997
28. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem M Planker JG Dos Santos P Piedbois B Paillot H Bodenstein HJ Schmoll H Bleiberg B Nordlinger ML Couvreor B Baron JA Wils 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657
29. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909
30. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe M Hughes J Mansi M Findlay A Hill J Oates M Nicolson T Hickish M O'Brien T Iveson M Watson C Underhill A Wardley M Meehan 1997 Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267
31. SS Wöhrer Raderer M Hejna 2004 Palliative chemotherapy for advanced gastric cancer Ann Oncol 15 1585 1595